drugset / Trial / NCT06945068
An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus
Phase 1
Not yet recruiting
19 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and efficacy of CD20xCD3 T-cell engager (GB261) in patients with refractory seropositive systemic lupus erythematosus.
Timeline
- Start
- 2025-06
- Primary completion
- 2025-06
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GB261 | Protein / enzyme biologic | — | Intravenous |